1198785-51-1Relevant articles and documents
Development of a large scale asymmetric synthesis of the glucocorticoid agonist BI 653048 BS H3PO4
Reeves, Jonathan T.,Fandrick, Daniel R.,Tan, Zhulin,Song, Jinhua J.,Rodriguez, Sonia,Qu, Bo,Kim, Soojin,Niemeier, Oliver,Li, Zhibin,Byrne, Denis,Campbell, Scot,Chitroda, Ashish,Decroos, Phil,Fachinger, Thomas,Fuchs, Victor,Gonnella, Nina C.,Grinberg, Nelu,Haddad, Nizar,Jaeger, Burkhard,Lee, Heewon,Lorenz, Jon C.,Ma, Shengli,Narayanan, Bikshandarkoil A.,Nummy, Larry J.,Premasiri, Ajith,Roschangar, Frank,Sarvestani, Max,Shen, Sherry,Spinelli, Earl,Sun, Xiufeng,Varsolona, Richard J.,Yee, Nathan,Brenner, Michael,Senanayake, Chris H.
, p. 3616 - 3635 (2013/06/04)
The development of a large scale synthesis of the glucocorticoid agonist BI 653048 BS H3PO4 (1·H3PO4) is presented. A key trifluoromethyl ketone intermediate 22 containing an N-(4-methoxyphenyl)ethyl amide was prepared by an enolization/bromine-magnesium exchange/electrophile trapping reaction. A nonselective propargylation of trifluoromethyl ketone 22 gave the desired diastereomer in 32% yield and with dr = 98:2 from a 1:1 diastereomeric mixture after crystallization. Subsequently, an asymmetric propargylation was developed which provided the desired diastereomer in 4:1 diastereoselectivity and 75% yield with dr = 99:1 after crystallization. The azaindole moiety was efficiently installed by a one-pot cross coupling/indolization reaction. An efficient deprotection of the 4-methoxyphenethyl group was developed using H3PO4/anisole to produce the anisole solvate of the API in high yield and purity. The final form, a phosphoric acid cocrystal, was produced in high yield and purity and with consistent control of particle size.
GLUCOCORTICOID MIMETICS, METHODS OF MAKING THEM, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF
-
Page/Page column 99, (2009/12/28)
Compounds of Formula I wherein R1, R2, X, and Y are as defined herein, or a tautomer, optical isomer, prodrug, co-crystal, or salt thereof; pharmaceutical compositions containing such compounds, and methods of modulating the glucocorticoid receptor function and methods of treating disease-states or conditions mediated by the glucocorticoid receptor function or characterized by inflammatory, allergic, or proliferative processes in a patient using these compounds.